Wild-type Reovirus

also known as PELA · pelareorep

Developed for: plasma cell myeloma · anaplastic oligodendroglioma · atypical teratoid rhabdoid tumor · childhood astrocytic tumor · childhood malignant neoplasm · childhood medulloblastoma · diffuse intrinsic pontine glioma · fallopian tube carcinoma
+5 more
· glioblastoma · melanoma · ovarian carcinoma · primary peritoneal carcinoma · primitive neuroectodermal tumor
Investigated by: National Cancer Institute (NCI) · Mayo Clinic · Oncolytics Biotech · University of Southern California

Trials 6

today NCT02514382 · Ph 1 NCT02444546 · Ph 1 NCT01533194 · Ph 1 NCT01240538 · Ph 1 NCT00602277 · Ph 1 NCT00651157 · Ph 2

20082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 15 trials
Phase 1	NCT02514382	Aug 2015 → Apr 2022	plasma cell myeloma	University of Southern California	Completed	No outcome recorded
Phase 1	NCT02444546	Jun 2015 → Jul 2018	anaplastic oligodendroglioma, atypical teratoid rhabdoid tumor, childhood astrocytic tumor, childhood medulloblastoma +3	Mayo Clinic	Completed	No outcome recorded
Phase 1	NCT01533194	Apr 2012 → Feb 2015	light chain deposition disease, plasma cell myeloma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01240538	Dec 2010 → Apr 2014	childhood malignant neoplasm	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00602277	Apr 2008 → Aug 2016	fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 21 trial
Phase 2	NCT00651157	Apr 2008 → Dec 2011	melanoma	National Cancer Institute (NCI)	Completed	No outcome recorded

Press releases naming this drug 77 releases

Date	Issuer	Release
2026-09-29	Oncolytics Biotech	Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy oncolyticsbiotech.com ↗
2026-09-10	Oncolytics Biotech	Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer oncolyticsbiotech.com ↗
2026-07-20	Oncolytics Biotech	Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer oncolyticsbiotech.com ↗
2026-06-16	Oncolytics Biotech	Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044 oncolyticsbiotech.com ↗
2026-06-01	Oncolytics Biotech	Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches oncolyticsbiotech.com ↗
2026-05-22	Oncolytics Biotech	Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors oncolyticsbiotech.com ↗
2026-04-06	Oncolytics Biotech	Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer oncolyticsbiotech.com ↗
2026-03-19	Oncolytics Biotech	Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026 oncolyticsbiotech.com ↗
2026-02-04	Oncolytics Biotech	Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer oncolyticsbiotech.com ↗
2026-01-12	Oncolytics Biotech	Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer oncolyticsbiotech.com ↗
2025-12-16	Oncolytics Biotech	Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer oncolyticsbiotech.com ↗
2025-11-19	Oncolytics Biotech	Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer oncolyticsbiotech.com ↗
2025-11-04	Oncolytics Biotech	Oncolytics Biotech® Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy oncolyticsbiotech.com ↗
2025-09-02	Oncolytics Biotech	Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors oncolyticsbiotech.com ↗
2025-08-08	Oncolytics Biotech	Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep oncolyticsbiotech.com ↗
2025-07-23	Oncolytics Biotech	Key Opinion Leader Event Highlights Pelareorep’s Compelling Pancreatic and Gastrointestinal Data And Future Potential oncolyticsbiotech.com ↗
2025-07-16	Oncolytics Biotech	Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep’s Effectiveness Across Multiple Tumor Types oncolyticsbiotech.com ↗
2025-07-08	Oncolytics Biotech	Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies oncolyticsbiotech.com ↗
2025-05-23	Oncolytics Biotech	Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep’s Unique Immune Activation Capabilities oncolyticsbiotech.com ↗
2025-04-24	Oncolytics Biotech	Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep’s Tumor-Fighting Mechanism of Action oncolyticsbiotech.com ↗
2025-04-10	Oncolytics Biotech	Oncolytics Biotech® Funds Pelareorep’s Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital oncolyticsbiotech.com ↗
2025-04-10	Oncolytics Biotech	Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers oncolyticsbiotech.com ↗
2024-12-18	Oncolytics Biotech	Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium oncolyticsbiotech.com ↗
2024-06-20	Oncolytics Biotech	Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer oncolyticsbiotech.com ↗
2024-05-24	Oncolytics Biotech	Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep’s Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action oncolyticsbiotech.com ↗
2024-05-15	Oncolytics Biotech	Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial oncolyticsbiotech.com ↗
2024-05-09	Oncolytics Biotech	Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer oncolyticsbiotech.com ↗
2024-04-11	Oncolytics Biotech	Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA oncolyticsbiotech.com ↗
2023-11-09	Oncolytics Biotech	Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep oncolyticsbiotech.com ↗
2023-11-09	Oncolytics Biotech	Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy oncolyticsbiotech.com ↗
2023-11-03	Oncolytics Biotech	Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC oncolyticsbiotech.com ↗
2023-10-16	Oncolytics Biotech	Oncolytics Biotech® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023 oncolyticsbiotech.com ↗
2023-06-22	Oncolytics Biotech	Oncolytics Biotech’s® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial oncolyticsbiotech.com ↗
2023-06-05	Oncolytics Biotech	Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate oncolyticsbiotech.com ↗
2023-05-25	Oncolytics Biotech	Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract oncolyticsbiotech.com ↗
2022-12-08	Oncolytics Biotech	Oncolytics Biotech’s ® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium oncolyticsbiotech.com ↗
2022-05-04	Oncolytics Biotech	Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep’s Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting oncolyticsbiotech.com ↗
2022-04-14	Oncolytics Biotech	Oncolytics Biotech® Announces Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors in Science Translational Medicine oncolyticsbiotech.com ↗
2022-03-24	Oncolytics Biotech	Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort oncolyticsbiotech.com ↗
2022-03-17	Oncolytics Biotech	Oncolytics Biotech® Announces Publication of Preclinical and Patient Data Demonstrating Pelareorep’s Stimulation of Natural Killer Cell Anti-Cancer Activity oncolyticsbiotech.com ↗
2022-03-09	Oncolytics Biotech	Oncolytics Biotech® Announces Phase 1b Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Proteasome Inhibitor Combination in Multiple Myeloma in an Abstract at the AACR Annual Meeting oncolyticsbiotech.com ↗
2022-01-27	Oncolytics Biotech	Oncolytics Biotech® Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer oncolyticsbiotech.com ↗
2021-12-15	Oncolytics Biotech	Oncolytics Biotech® Announces the Presentation of Preclinical Data Demonstrating the Synergistic Anti-Leukemic Effects of Pelareorep Combined with Azacitidine at the 2021 American Society of Hematology Annual Meeting oncolyticsbiotech.com ↗
2021-11-03	Oncolytics Biotech	Oncolytics Biotech® Doses First Patient in Phase 1/2 GOBLET Study Evaluating Pelareorep-anti-PD-L1 Combination Therapies in Gastrointestinal Cancers oncolyticsbiotech.com ↗
2021-10-14	Oncolytics Biotech	Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer oncolyticsbiotech.com ↗
2021-09-20	Oncolytics Biotech	Oncolytics Biotech® Announces Preclinical Data Demonstrating the Synergistic Immunotherapeutic Effects of Pelareorep Combined with Radiotherapy oncolyticsbiotech.com ↗
2021-05-20	Oncolytics Biotech	Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer oncolyticsbiotech.com ↗
2021-04-12	Oncolytics Biotech	Oncolytics Biotech® Presents Preclinical Data on Pelareorep-based Combination Therapies at the AACR Annual Meeting oncolyticsbiotech.com ↗
2021-04-05	Oncolytics Biotech	Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid Tumors oncolyticsbiotech.com ↗
2021-02-23	Oncolytics Biotech	Oncolytics Biotech® Reports Preclinical Data Demonstrating the Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors oncolyticsbiotech.com ↗
2020-12-09	Oncolytics Biotech	Oncolytics and SOLTI Report Clinical Synergy of Pelareorep with Checkpoint Inhibitors at the 2020 San Antonio Breast Cancer Symposium oncolyticsbiotech.com ↗
2020-11-09	Oncolytics Biotech	Oncolytics Biotech® and SOLTI Present Clinical Breast Cancer Data Highlighting Pelareorep-Induced Anti-Tumor T Cell Responses at The Society for Immunotherapy of Cancer Annual Meeting oncolyticsbiotech.com ↗
2020-10-27	Oncolytics Biotech	Oncolytics Biotech® Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche’s Anti-PD-L1 Checkpoint Inhibitor oncolyticsbiotech.com ↗
2020-08-26	Oncolytics Biotech	Oncolytics Biotech® Doses First Patient in Phase 2 IRENE Study Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer oncolyticsbiotech.com ↗
2020-06-25	Oncolytics Biotech	Oncolytics Biotech® Announces Investigator Sponsored Phase 2 Trial Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer oncolyticsbiotech.com ↗
2020-06-23	Oncolytics Biotech	Oncolytics Biotech® Doses First Patient in Phase 2 BRACELET-1 Study Evaluating Pelareorep-Based Combination Therapies in Metastatic Breast Cancer oncolyticsbiotech.com ↗
2020-06-04	Oncolytics Biotech	Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting the Induction of Rapid and Persistent Immune Responses With Systemic Pelareorep Treatment oncolyticsbiotech.com ↗
2020-05-26	Oncolytics Biotech	Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer at the ESMO Breast Cancer Virtual Meeting oncolyticsbiotech.com ↗
2020-05-04	Oncolytics Biotech	Oncolytics Biotech® to Present Clinical Findings of Pelareorep-Induced Immune Response in Breast Tumors at the ESMO Breast Cancer Virtual Meeting oncolyticsbiotech.com ↗
2020-04-02	Oncolytics Biotech	Oncolytics Biotech® Announces Publication of Pelareorep’s Clinical Benefit Against KRAS Mutated Colorectal Cancer oncolyticsbiotech.com ↗
2020-01-27	Oncolytics Biotech	Oncolytics Biotech® Announces Statistically Significant Data Identifying CEACAM6 as a Prospective Prognostic Biomarker for Pelareorep in the Treatment of Pancreatic Adenocarcinoma oncolyticsbiotech.com ↗
2020-01-13	Oncolytics Biotech	Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep’s Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma oncolyticsbiotech.com ↗
2019-12-03	Oncolytics Biotech	Oncolytics Biotech(R) Presents Clinical Data at the Fifth Annual Oncolytic Virotherapy Conference Highlighting Definitive Evidence of Systemic Delivery and Replication of Pelareorep in Tumor Tissue oncolyticsbiotech.com ↗
2019-11-06	Oncolytics Biotech	Oncolytics Biotech(R) Announces Publication of Positive REO 024 Study Results for Pelareorep in Combination with Keytruda(R) in Patients with Advanced Pancreatic Adenocarcinoma oncolyticsbiotech.com ↗
2019-10-15	Oncolytics Biotech	Oncolytics Biotech(R) Presents Clinical Data Highlighting the Effectiveness of Intravenous Delivery to and Replication of Pelareorep in Tumors oncolyticsbiotech.com ↗
2019-07-23	Oncolytics Biotech	Oncolytics Biotech(R) Announces Preliminary AWARE-1 Trial Data Demonstrating Viral Replication and Promotion of Inflammation Following Systemic Administration of Pelareorep When Combined with Tecentriq(R) oncolyticsbiotech.com ↗
2019-06-05	Oncolytics Biotech	Oncolytics Biotech (R) Announces Study to Investigate Combination of Pelareorep and Avelumab in Metastatic Breast Cancer in Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer oncolyticsbiotech.com ↗
2019-04-08	Oncolytics Biotech	Oncolytics Biotech(R) Announces First Patient Treated in Company’s AWARE-1 Window of Opportunity Study of Pelareorep in Breast Cancer oncolyticsbiotech.com ↗
2019-03-28	Oncolytics Biotech	Oncolytics Biotech (R) Announces a Publication Highlighting Synergistic Effect of Pelareorep with a Proteasome Inhibitor in Preclinical Models of Multiple Myeloma oncolyticsbiotech.com ↗
2018-12-12	Oncolytics Biotech	Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and the Checkpoint Inhibitor Opdivo® in Multiple Myeloma oncolyticsbiotech.com ↗
2018-12-03	Oncolytics Biotech	Oncolytics Biotech® Announces Increased PD-L1 Expression When Combining Pelareorep with a Proteasome Inhibitor in Poster Presentation at the 60th American Society of Hematology Annual Meeting & Exposition oncolyticsbiotech.com ↗
2018-11-26	Oncolytics Biotech	Oncolytics Biotech® Announces First Patient Treated in Phase 2 Study Combining Pelareorep and Keytruda® in Advanced Pancreatic Cancer oncolyticsbiotech.com ↗
2018-11-01	Oncolytics Biotech	Oncolytics Biotech® Announces Abstract for ASH Annual Meeting & Exposition Demonstrating Pelareorep Increases PD-L1 Expression When Combined with a Proteasome Inhibitor oncolyticsbiotech.com ↗
2018-10-22	Oncolytics Biotech	Oncolytics Biotech® Announces Positive Clinical Trial Results for Pelareorep in Patients with KRAS Mutant Metastatic Colorectal Cancer for Presentation at ESMO 2018 oncolyticsbiotech.com ↗
2018-10-11	Oncolytics Biotech	Oncolytics Biotech® Announces Publication of Positive Clinical Results for Pelareorep in Abstract for ESMO 2018 Congress oncolyticsbiotech.com ↗
2018-09-10	Oncolytics Biotech	Oncolytics Biotech® Collaborates with SOLTI to Conduct a Window of Opportunity Study in Breast Cancer with Pelareorep oncolyticsbiotech.com ↗
2018-05-10	Oncolytics Biotech	Oncolytics Biotech® Receives Special Protocol Assessment Agreement from FDA for Phase 3 Clinical Trial of Pelareorep In Metastatic Breast Cancer oncolyticsbiotech.com ↗

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

Field	Value	Cited text
Known as	Wild-type Reovirus	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01533194 ↗ 5 NCT00651157 ↗ NCT00602277 ↗ NCT01240538 ↗ NCT02444546 ↗ NCT02514382 ↗
Known as	PELA	“Our preclinical studies showed that the oncolytic reovirus formulation pelareorep (PELA) has significant immunomodulatory anti-myeloma activity.” PMID 37812476 ↗ Dec 2023
Known as	pelareorep	“Our preclinical studies showed that the oncolytic reovirus formulation pelareorep (PELA) has significant immunomodulatory anti-myeloma activity.” PMID 37812476 ↗ Dec 2023
Modality	Other / unclassified	“viral therapy” NCT00602277 ↗
Route	Intravenous	“intravenous (IV)” NCT00602277 ↗